Ferroptosis in Cancer Therapy: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Ferroptosis, a distinct form of regulated cell death driven by iron-dependent lipid peroxidation, has gained significant attention as a potential target in cancer therapy. Understanding the molecular mechanisms, clinical significance, and translational advances surrounding ferroptosis offers promising avenues to overcome therapeutic resistance and selectively eradicate malignant cells. This review synthesizes current evidence, with a focus on the interplay between ferroptosis and cancer pathology, epidemiological trends, clinical features, diagnostic approaches, and evolving treatment paradigms. We discuss the integration of ferroptosis-inducing strategies in oncologic practice, highlight recent advances, and provide guideline-based recommendations for the clinical application of ferroptosis modulation in cancer management.

Introduction

Conventional cancer therapies often encounter the challenge of resistance and relapse, prompting the ongoing search for novel cell death pathways amenable to therapeutic manipulation. Ferroptosis, first characterized in 2012, is a non-apoptotic, iron-dependent cell death process marked by the accumulation of lethal lipid peroxides. Unlike apoptosis or necrosis, ferroptosis is governed by distinct metabolic and redox regulatory networks, including glutathione peroxidase 4 (GPX4), system Xc–, and iron homeostasis. The relevance of ferroptosis in cancer therapy lies in its ability to overcome resistance to traditional cytotoxic agents and its selective toxicity toward tumor cells with aberrant metabolic profiles. As our understanding deepens, ferroptosis emerges as a promising target in precision oncology, with implications for both solid and hematologic malignancies.

Epidemiology / Disease Burden

Cancer remains the leading cause of global morbidity and mortality, with an estimated 19.3 million new cases and 10 million deaths worldwide in 2020. Tumor heterogeneity and adaptive resistance mechanisms significantly limit the efficacy of established treatment modalities. While the epidemiology of ferroptosis susceptibility is not fully delineated, preclinical studies suggest that numerous cancer types including hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, and triple-negative breast cancer demonstrate heightened vulnerability to ferroptosis induction. The clinical burden of treatment-refractory cancers underscores the urgent need for novel mechanistically targeted therapies, such as those exploiting ferroptotic pathways.

Pathophysiology

Ferroptosis is initiated by the iron-catalyzed generation of reactive oxygen species (ROS) that trigger peroxidation of polyunsaturated fatty acids (PUFAs) in cellular membranes. Key regulators include: (1) iron metabolism proteins (transferrin receptor, ferritin, ferroportin), (2) system Xc–, a cystine/glutamate antiporter maintaining glutathione (GSH) synthesis, and (3) GPX4, an essential enzyme neutralizing lipid peroxides. Disruption of system Xc– or GPX4 depletes GSH, compromising antioxidant defenses and precipitating ferroptosis. Tumor cells, particularly those with high metabolic demands or altered redox states, are often susceptible to ferroptosis due to dysregulated iron metabolism and lipid composition. Oncogenic signaling pathways (e.g., p53, RAS) further modulate ferroptosis sensitivity, highlighting the intricate crosstalk between tumor genetics and ferroptotic susceptibility.

Risk Factors

Intrinsic and extrinsic factors influence ferroptosis sensitivity in cancer. Tumor-specific risk factors include mutations in p53, RAS, and KEAP1-NRF2 axis, which alter redox balance and iron metabolism. Overexpression of transferrin receptor or suppression of ferroportin increases labile iron pools, predisposing cells to ferroptosis. Metabolic reprogramming in cancer, such as enhanced PUFA synthesis or increased cystine uptake, further modulates ferroptotic thresholds. Exogenous factors, including certain chemotherapeutics (e.g., sorafenib, erastin) and radiation, can promote ferroptosis, whereas upregulation of antioxidant systems or iron chelation confers resistance. Patient-specific variables such as comorbid metabolic disorders and prior treatment exposures may also influence ferroptosis outcomes.

Clinical Features

Ferroptosis does not manifest with specific clinical symptoms in patients; rather, its relevance is observed at the cellular and tissue levels. In preclinical models, ferroptosis induction leads to rapid tumor regression, especially in cancers resistant to apoptosis-inducing agents. Histologically, ferroptotic cells exhibit shrunken mitochondria, increased membrane density, and diminished cristae distinct from apoptotic or necrotic morphologies. In clinical settings, evidence of ferroptosis may be inferred from biomarker analysis (e.g., lipid peroxidation products, altered iron metabolism markers), though direct assessment in patients remains investigational. The clinical translation of ferroptosis-based strategies is ongoing, with early-phase trials assessing safety and tumor response.

Diagnosis

Diagnosis of ferroptosis is primarily established in research settings via morphological, biochemical, and molecular criteria. Transmission electron microscopy reveals characteristic mitochondrial changes, while biochemical assays detect increased malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and depletion of GSH. Molecular markers include decreased GPX4 activity, increased ACSL4 expression, and altered iron handling proteins. In translational research, surrogate biomarkers such as plasma lipid peroxidation products and iron status are being explored. Clinically, diagnostic approaches integrating functional imaging, liquid biopsy, and molecular profiling may enable the identification of ferroptosis-prone tumors in the future, facilitating patient stratification for ferroptosis-targeted therapies.

Treatment & Management

Ferroptosis induction represents a novel therapeutic strategy in oncology. Pharmacologic inducers include erastin (system Xc– inhibitor), RSL3 (GPX4 inhibitor), sorafenib, and sulfasalazine. These agents disrupt redox homeostasis and promote lethal lipid peroxidation in cancer cells. Combination approaches pairing ferroptosis inducers with immunotherapy, chemotherapy, or targeted agents have demonstrated synergistic antitumor effects in preclinical models. Conversely, ferroptosis inhibitors (e.g., ferrostatin-1, liproxstatin-1) may mitigate off-target toxicity in normal tissues. Clinical trials are evaluating the safety, efficacy, and optimal integration of ferroptosis modulation in the treatment of solid and hematologic malignancies, with emphasis on biomarker-driven patient selection.

Recent Advances / Emerging Therapies

Recent years have witnessed substantial progress in the development of ferroptosis-based therapeutics. Nanoparticle delivery systems enhance the tumor-specific accumulation of ferroptosis inducers and reduce systemic toxicity. Combinatorial regimens targeting ferroptosis alongside immune checkpoint inhibitors or DNA damage response modulators show promise in overcoming resistance. Identification of predictive biomarkers such as ACSL4, SLC7A11, and GPX4 expression enables personalized ferroptosis-targeted approaches. Furthermore, ongoing studies are exploring the potential of autophagy- and metabolism-modulating agents to synergize with ferroptosis induction. These advances underscore the translational potential of ferroptosis modulation in precision cancer therapy.

Guideline Recommendations

While no standardized guidelines for ferroptosis-targeted therapy currently exist, emerging consensus recommends integrating ferroptosis modulation into the multi-modal management of refractory and high-risk cancers, particularly those with validated susceptibility markers. Patient selection should be guided by molecular profiling, iron metabolism assessment, and tumor biology. Participation in clinical trials evaluating ferroptosis inducers or combination regimens is strongly encouraged. Multidisciplinary collaboration among oncologists, pathologists, and translational researchers is essential for the safe and effective clinical implementation of ferroptosis-based strategies.

Conclusion

Ferroptosis represents a paradigm shift in the understanding and treatment of cancer, offering a mechanistically distinct and clinically actionable cell death pathway. Advances in elucidating its molecular underpinnings and translational potential have paved the way for innovative therapies targeting ferroptosis in resistant and aggressive malignancies. Ongoing research and clinical trials are critical to optimizing ferroptosis-targeted interventions, refining patient selection, and integrating these strategies into evidence-based oncologic practice. As the field evolves, ferroptosis holds considerable promise for improving cancer outcomes and addressing unmet therapeutic needs in oncology.